PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025. Since the first quarter of 2020, ImmuCell has been providing a preliminary look at its unaudited top line results soon after the close of the quarter and the Company expects to ...

Core Viewpoint - ImmuCell Corporation is shifting its strategic focus towards the First Defense product line and away from Re-Tain, with upcoming discussions on its unaudited sales results for 2025 [2][3]. Group 1: Strategic Changes - The company announced a strategic change in focus towards the First Defense product line on December 24, 2025 [2]. - The upcoming conference call on January 9, 2026, will address this strategic shift and the unaudited topline sales results for the fourth quarter and full year ended December 31, 2025 [3]. Group 2: Financial Results and Conference Calls - ImmuCell plans to release its full unaudited financial results for the quarter and year ended December 31, 2025, after the market closes on February 25, 2026 [4]. - A conference call to discuss these financial results is scheduled for February 26, 2026, at 9:00 AM ET [4]. Group 3: Company Overview - ImmuCell Corporation focuses on creating scientifically proven products that enhance cattle health and productivity, specifically through its First Defense product, which provides Immediate Immunity™ to newborn dairy and beef calves [5].

Core Viewpoint - Elanco Animal Health Incorporated will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, with key executives representing the company [1]. Company Overview - Elanco Animal Health is a global leader in animal health, focusing on innovating and delivering products and services for the prevention and treatment of diseases in farm animals and pets [3]. - The company has a 70-year heritage in animal health and aims to create value for farmers, pet owners, veterinarians, stakeholders, and society [3]. - Elanco's vision is centered around "Food and Companionship Enriching Life," with a commitment to making a meaningful impact on local and global communities [3]. Event Details - The conference will feature a live audio webcast available in the "Events and Presentations" section of Elanco's investor website, with a replay accessible for a limited time after the event [2].

Group 1: RenaissanceRe (RNR) - RenaissanceRe provides property-catastrophe reinsurance globally on an excess of loss basis [1] - The company has a Zacks Rank 1 (Strong Buy) and a Growth Score of A [2] - The Zacks Consensus Estimate for its current year earnings has increased by 12.9% over the last 60 days [1] Group 2: Great Lakes Dredge & Dock (GLDD) - Great Lakes Dredge & Dock is the largest provider of dredging services in the US [2] - The company also holds a Zacks Rank 1 and a Growth Score of A [3] - The Zacks Consensus Estimate for its current year earnings has increased by 6.9% over the last 60 days [2] Group 3: Phibro Animal Health (PAHC) - Phibro Animal Health is a leading global diversified animal health and mineral nutrition company [3] - The company carries a Zacks Rank 1 and has a Growth Score of B [4] - The Zacks Consensus Estimate for its current year earnings has increased by 9.1% over the last 60 days [3]

Zoetis Inc. (NYSE:ZTS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. BofA Downgrades Zoetis (ZTS) to Neutral, Cuts Price Target Budimir Jevtic/Shutterstock.com On December 15, BofA downgraded Zoetis Inc. (NYSE:ZTS) to Neutral from Buy and lowered its price target to $135 from $165. In other news, on December 5, Zoetis Inc. (NYSE:ZTS) announced that Health Canada approved Portela™ (relfovetmab injection) for the relief of pain linked to osteoarthritis, or OA, in cats. Portela is d ...

Core Viewpoint - Zoetis Inc. will host a webcast and conference call to discuss its fourth quarter and full year 2025 financial results on February 12, 2026, led by CEO Kristin Peck and CFO Wetteny Joseph [1]. Group 1: Financial Results Announcement - The conference call is scheduled for 8:30 a.m. (ET) on February 12, 2026, where financial analysts will have the opportunity to ask questions [1]. - Investors and the public can access the live webcast through the Zoetis website, with pre-registration available starting today [2]. Group 2: Company Overview - Zoetis is recognized as the world's leading animal health company, focusing on advancing care for animals and supporting those who raise and care for them [3]. - The company has a strong portfolio and pipeline of medicines, vaccines, diagnostics, and technologies, impacting over 100 countries [3]. - In 2024, Zoetis generated revenue of $9.3 billion and employs approximately 13,800 people [3].

Core Viewpoint - Zomedica Corp. has launched the VETGuardian PLUS monitor, enhancing its Zero Touch™ patient monitoring platform for veterinary clinics, aimed at improving workflow efficiency and clinical confidence while supporting long-term growth strategy [1] Group 1: Product Launch - The VETGuardian PLUS monitor is the next generation of the original VETGuardian® system [1] - New features have been added to improve ease of use and access to patient data [1] Group 2: Company Strategy - The launch of the VETGuardian PLUS monitor aligns with Zomedica's long-term growth strategy [1] - The product aims to strengthen clinical confidence in veterinary practices [1]

Zoetis Inc. (NYSE:ZTS) is included among the 15 Dividend Stocks with Low Payout Ratios and Strong Upside. Zoetis (ZTS) Positioned Within Morgan Stanley’s 2026 Healthcare Playbook Budimir Jevtic/Shutterstock.com On December 18, Morgan Stanley lowered its price target on Zoetis Inc. (NYSE:ZTS) to $160 from $175 and kept an Overweight rating. In its year-ahead outlook, the firm said healthcare technology and providers offer an “attractive backdrop for alpha-generation opportunities” in 2026. Managed care i ...

Core Insights - Mountain Valley MD Holdings Inc. (MVMD) is focused on disciplined execution across its business lines, aiming for measured growth in product development and commercialization [1] Nutraceuticals - MVMD's Quicksome™ technology optimizes molecule delivery in sublingual nutraceutical applications, enhancing efficacy, precise dosing, and dose sparing [2][3] - The company has an exclusive manufacturing and licensing agreement with a U.S.-based GMP production partner to support Quicksome™ formulations [3] - MVMD is advancing its nutraceutical strategy through partnerships, including a novel testosterone formulation for men, expected to launch in the first half of 2026 [5] Agriculture - MVMD is commercializing its Agrarius™ plant signaling technology, which aims to increase crop yields and reduce fertilizer usage [8] - Trials in Brazil have shown that Agrarius-treated citrus orchards achieved over 50% productivity gains and improved resilience to stress [11][12] - The company is also conducting trials in Colombia, demonstrating improved pasture quality and vegetation health [17] Husbandry Animals and Aquatic Species - MVMD's Soluvec™ 1% formulation, utilizing Quicksol™ technology, aims to provide safer administration of ivermectin for husbandry animals and aquatic species [18] - The company has entered into a licensing agreement in Bangladesh for the production and distribution of Soluvec™ products [19] - Despite initial challenges in commercial traction, MVMD is focusing on royalty-based licensing opportunities for Soluvec™ [21][24]

Group 1: RenaissanceRe Holdings Ltd. (RNR) - RenaissanceRe Holdings is an insurance and reinsurance company with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 27.4% over the last 60 days [1] - The company has a PEG ratio of 1.66, which is lower than the industry average of 1.82, and possesses a Growth Score of B [1] Group 2: Phibro Animal Health Corporation (PAHC) - Phibro Animal Health Corporation operates in the animal health and mineral nutrition sector and holds a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has risen by 9.1% over the last 60 days [2] - The company has a PEG ratio of 1.07, significantly lower than the industry average of 2.68, and has a Growth Score of B [2] Group 3: Commercial Metals Company (CMC) - Commercial Metals Company is involved in steel and metals manufacturing and also carries a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings has increased by 21.3% over the last 60 days [3] - The company has a PEG ratio of 0.39, which is much lower than the industry average of 1.52, and possesses a Growth Score of B [3]